Literature DB >> 19384324

Transplantation: sirolimus plus calcineurin inhibitors in transplantation.

William Braun1.   

Abstract

A recent study reported that combination therapy with sirolimus plus either tacrolimus or ciclosporin resulted in effective immunosuppression in high-risk renal allograft recipients. Does such combination therapy really represent an advance in immunosuppressive therapy for these individuals?

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19384324     DOI： 10.1038/nrneph.2009.55

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


  13 in total

Review 1.  Immunosuppressive drugs for kidney transplantation.

Authors:  Philip F Halloran
Journal:  N Engl J Med       Date:  2004-12-23       Impact factor: 91.245

2.  Assessing glomerular filtration rate by estimation equations in kidney transplant recipients.

Authors:  E D Poggio; X Wang; D M Weinstein; N Issa; V W Dennis; W E Braun; P M Hall
Journal:  Am J Transplant       Date:  2006-01       Impact factor: 8.086

Review 3.  C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation.

Authors:  G A Levy
Journal:  BioDrugs       Date:  2001       Impact factor: 5.807

Review 4.  The clinical benefits of cyclosporine C2-level monitoring: a systematic review.

Authors:  Simon R Knight; Peter J Morris
Journal:  Transplantation       Date:  2007-06-27       Impact factor: 4.939

5.  Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors.

Authors:  K C Mange; M M Joffe; H I Feldman
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

6.  Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus.

Authors:  Herwig-Ulf Meier-Kriesche; Jesse D Schold; Titte R Srinivas; Richard J Howard; Shiro Fujita; Bruce Kaplan
Journal:  Am J Transplant       Date:  2005-09       Impact factor: 8.086

7.  Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations.

Authors:  Hemangshu Podder; Stanislaw M Stepkowski; Kimberly L Napoli; James Clark; Regina R Verani; Ting-Chao Chou; Barry D Kahan
Journal:  J Am Soc Nephrol       Date:  2001-05       Impact factor: 10.121

8.  A multicenter, prospective study of C2-monitored cyclosporine microemulsion in a U.S. population of de novo renal transplant recipients.

Authors:  Flavio Vincenti; Robert Mendez; John Curtis; Jimmy Light; Thomas Pearson; You-Min Wu; Stephen M Katz; Enver Akalin; Robert Esterl; Kristene Gugliuzza; Fuad Shihab; Stanley Jordan; Johann Jonsson; Ernesto Molmenti; Ralph Barbeito
Journal:  Transplantation       Date:  2005-10-15       Impact factor: 4.939

9.  Long-term graft outcomes after steroid withdrawal in African American kidney transplant recipients receiving sirolimus and tacrolimus.

Authors:  Donald E Hricik; Joshua J Augustine; Thomas C Knauss; Kenneth A Bodziak; Mark Aeder; Christopher Siegel; James A Schulak
Journal:  Transplantation       Date:  2007-02-15       Impact factor: 4.939

10.  Identification of high- and low-risk second kidney grafts.

Authors:  R J Mahoney; D J Norman; B W Colombe; M R Garovoy; D A Leeber
Journal:  Transplantation       Date:  1996-05-15       Impact factor: 4.939
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.